Advancing your drug or vaccine candidate from late-stage discovery into the clinic is one of the most critical steps in development. To maximize your chances of success, it is essential to de-risk your drug candidates as early as possible. This meeting will provide insights and solutions on how to de-risk your development and how to accelerate your path to FIH (First-in-Human) clinical studies. You will also learn how in silico and in vitro protein design and optimization tools can help you to identify and mitigate manufacturing, development and immunogenicity liabilities and how to improve the quality and safety of your therapeutic proteins
Date: Thursday, 9th of March, 2023
Time: 9:00 – 11:00 CET
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Meeting room: Auditorium
Program
| 9:00 | Networking, registration and light breakfast |
| 9:30 | Welcome David Munis Zepernick, Head of Member Engagement and Communication, Medicon Valley Alliance Vidya Pawar Menon, Business Development Manager, Lonza |
| 9:35 | Developability and Immunosafety: Don’t let them threaten your drug development plans Noel Smith, Head of Immunology, Lonza |
| 10:05 | Q&A |
| 10:20 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Vidya Pawar Menon, Business Development Manager
Vidya is looking after Business Development for Lonza’s Biologics business in the Nordics region. She is your point of contact for Lonza’s Biologics offering including Early Development Services, Mammalian and Microbial Drug Substance manufacturing, Bioconjugation, and Drug Product Fill and Finish. This includes monoclonal antibodies, complex bi-/tri-specific and other fusion molecule/ protein formats, Antibody Drug Conjugates and mRNA therapeutics. Vidya has a background in molecular biology with a PhD from Oxford Brookes University, UK. |
 |
Noel Smith, Head of Immunology
Noel completed his PhD and subsequent post-doctoral studies at the University of Cambridge in the field of metabolic disease. Noel joined Lonza in 2009 and was involved in the setup of the human primary cell-based assay platform and now Heads the Immunology group, which develops assays to screen products for immunogenicity and immunotoxicity risk. The Lonza Cambridge site is focused on the development and provision of services to support the development of new biotherapeutic proteins and vaccines, with a particular focus on immunosafety, manufacturability and protein expression. |
| Organized by | In collaboration with |
 |
 |